Thomas Redelmeider, PhD
Founder, President & CEO
Prior to joining Cuprous, Dr. Redelmeier was the President & CEO of Transferra Nanosciences (formerly known as Northern Lipids). He led the company for 20 years, transforming it into a leader in the provision of Contract Research/Manufacturing services specifically related to lipid nanoparticle formulations of active pharmaceutical ingredients. The company was sold to EVONIK in 2016, where it continues to be active in this area.
Dr. Redelmeier has more than 30 years of experience studying lipid nanoparticle systems including 20 years at Transferra where he was involved with more than 30 programs that were in preclinical and/or clinical development. He completed his PhD studies at the University of British Columbia, working with Dr. Pieter Cullis. He is the author of more than 25 peer reviewed papers, and has co-authored a book on Percutaneous Absorption (Karger 1996).
Michael Abrams, PhD
Vice President, Research
Dr. Abrams was the former President and CEO of Inimex Pharmaceuticals Inc., Chief Innovation Officer and VP for Research and Development at CDRD Ventures Inc., and Managing Director of Arbutus Bipharma Corporation. Abrams completed his PhD in Chemistry at the Massachusetts Institute of Technology and has extensive experience working in biotechnology companies and commercialization of pharmaceutical products. Dr. Abrams was the founding CEO of AnorMED Inc. and led that company for 10 years. AnorMED developed the FDA-approved stem cell mobilizing drug, Mozobil, and was acquired by Genzyme in 2006 for over $500M.
Marcel Bally, PhD
Dr. Bally is Head and Distinguished Scientist of the Department of Experimental Therapeutics at the BC Cancer Agency. As an independent researcher with experience in academia and industry, he has focused his career on development of much needed novel drugs, drug combinations and drug delivery systems designed for use in patients with metastatic cancer. He has generated over 550 scientific articles, abstracts, book chapters and patents that have been cited over 17,400 times. He has been a PI/Co-PI on grants valued at over $50M and he has participated in private sector funding for companies that he co-founded (Lipex, Inex (now Arbutus), Northern Lipids (renamed Transferra and purchased by Evonik in 2016), Celator (purchased by Jazz in 2016 for $1.4 billion) and most recently Cuprous Pharmaceuticals. This effort resulted in three approved drugs: Myocet®- for metastatic breast cancer, Marqibo®- for relapsed ALL, and CPX-351 (VYXEOS™) which some believe will replace the standard of care for high risk AML.
Ada Leung, PhD
Mitacs Elevate Fellow
Dr. Leung is an inventor of the Metaplex technology. She completed her PhD at the University of British Columbia; where she was awarded a prestigious Vanier Canada Graduate Scholarship. During her PhD, she contributed to over 10 peer-reviewed publications. Her thesis work involved identifying and validating novel targets that could be used to enhance platinum-based chemotherapy against non-small cell lung cancer. In the final years of her PhD, Dr. Leung undertook another project which contributed to the development of the Metaplex technology. She is currently a Mitacs Elevate Fellow (supervised by Dr. Chris Orvig (UBC), which is co-funded by Cuprous. Working with Dr. Orvig and Dr. Abrams she is broadening her knowledge in metal chemistry and commercialization of technology in the life sciences sector.